[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2004096254A3 - Transferrin conjugates for tumor treatment - Google Patents

Transferrin conjugates for tumor treatment Download PDF

Info

Publication number
WO2004096254A3
WO2004096254A3 PCT/IB2004/001954 IB2004001954W WO2004096254A3 WO 2004096254 A3 WO2004096254 A3 WO 2004096254A3 IB 2004001954 W IB2004001954 W IB 2004001954W WO 2004096254 A3 WO2004096254 A3 WO 2004096254A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumor
ligand
binds
subject
cells
Prior art date
Application number
PCT/IB2004/001954
Other languages
French (fr)
Other versions
WO2004096254A2 (en
Inventor
Jasbir Sandhu
Original Assignee
Xpression Antibody Therapeutic
Jasbir Sandhu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/429,497 external-priority patent/US20040219098A1/en
Priority claimed from US10/429,482 external-priority patent/US20040219097A1/en
Priority claimed from US10/429,662 external-priority patent/US20040220085A1/en
Priority claimed from US10/429,515 external-priority patent/US20040219099A1/en
Priority claimed from US10/429,655 external-priority patent/US20040220121A1/en
Priority claimed from US10/429,598 external-priority patent/US20040219100A1/en
Priority claimed from US10/429,654 external-priority patent/US20040220390A1/en
Priority claimed from US10/429,653 external-priority patent/US20040219102A1/en
Priority claimed from US10/429,659 external-priority patent/US20040219103A1/en
Application filed by Xpression Antibody Therapeutic, Jasbir Sandhu filed Critical Xpression Antibody Therapeutic
Publication of WO2004096254A2 publication Critical patent/WO2004096254A2/en
Publication of WO2004096254A3 publication Critical patent/WO2004096254A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The instant invention provides compositions for inhibiting tumor growth or for imaging tumors in a subject and methods of using the same. In one embodiment, the composition comprises transferrin, the anti-tumor agent, and at least one other ligand that selectively binds to tumor cells, or to the endothelial cells of the tumor vasculature. Also provided is a method of inhibiting growth of tumor cells in a mammalian subject, particularly a human subject. The method comprises administering a composition of the present invention to the subject. Also provided is a method of visualizing tumor tissue in a subject. The method comprises administering a composition that comprises radiolabled transferrin operatively linked to a ligand that binds to tumor cells, or a ligand that binds to the endothelial cells of the tumor vasculature, or, preferably a ligand that binds to tumor cells and a ligand that binds to endothelial cells of the tumor vasculature, detecting the radiolabel, and visualizing the tumor tissue.
PCT/IB2004/001954 2003-05-02 2004-05-03 Transferrin conjugates for tumor treatment WO2004096254A2 (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US10/429,653 2003-05-02
US10/429,655 2003-05-02
US10/429,659 2003-05-02
US10/429,497 US20040219098A1 (en) 2003-05-02 2003-05-02 Methods for the treatment of tumors
US10/429,482 US20040219097A1 (en) 2003-05-02 2003-05-02 Composition useful for the diagnosis, imaging and treatment of tumors
US10/429,662 US20040220085A1 (en) 2003-05-02 2003-05-02 Compositions for nucleic acid delivery
US10/429, 2003-05-02
US10/429,515 US20040219099A1 (en) 2003-05-02 2003-05-02 Method for the treatment of tumors
US10/429,482 2003-05-02
US10/429,598 2003-05-02
US10/429,655 US20040220121A1 (en) 2003-05-02 2003-05-02 Methods for drug delivery
US10/429,598 US20040219100A1 (en) 2003-05-02 2003-05-02 Composition useful for the treatment of tumors
US10/429,654 US20040220390A1 (en) 2003-05-02 2003-05-02 Composition useful for the treatment of tumors
US10/429,653 US20040219102A1 (en) 2003-05-02 2003-05-02 Compositions for drug delivery
US10/429,654 2003-05-02
US10/429,497 2003-05-02
US10/429,515 2003-05-02
US10/429,659 US20040219103A1 (en) 2003-05-02 2003-05-02 Methods useful for the diagnosis, imaging and treatment of tumors
US10/429,662 2003-05-02

Publications (2)

Publication Number Publication Date
WO2004096254A2 WO2004096254A2 (en) 2004-11-11
WO2004096254A3 true WO2004096254A3 (en) 2006-03-23

Family

ID=33425933

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001954 WO2004096254A2 (en) 2003-05-02 2004-05-03 Transferrin conjugates for tumor treatment

Country Status (1)

Country Link
WO (1) WO2004096254A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006217612A1 (en) * 2005-02-22 2006-08-31 Ge Healthcare Limited Radiolabeled gallium complexes, methods for synthesis and use for PET imaging of EGFR expression in malignant tumors
US9155798B2 (en) 2007-08-24 2015-10-13 Regents Of The University Of Minnesota Receptor-targeting reagents containing epidermal factor receptor-binding agents and IL-13 receptor-binding agents or IL-4 receptor-binding agents
CA2818583A1 (en) * 2010-11-19 2012-05-24 Venus Remedies Limited Novel conjugates for targeted drug delivery
TWI559928B (en) * 2014-08-20 2016-12-01 Academia Sinica Methods for enhancing permeability to blood-brain barrier and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
WO1996008274A2 (en) * 1994-09-13 1996-03-21 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
WO2002094271A1 (en) * 2001-05-15 2002-11-28 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer
WO2003032899A2 (en) * 2001-10-17 2003-04-24 Faulk Pharmaceuticals, Inc Methods and materials for targeting and affecting selected cells

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522750A (en) * 1984-02-21 1985-06-11 Eli Lilly And Company Cytotoxic compositions of transferrin coupled to vinca alkaloids
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
WO1996008274A2 (en) * 1994-09-13 1996-03-21 Prizm Pharmaceuticals, Inc. Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
WO2002094271A1 (en) * 2001-05-15 2002-11-28 Faulk Pharmaceuticals, Inc. Targeted delivery of bioaffecting compounds for the treatment of cancer
WO2003032899A2 (en) * 2001-10-17 2003-04-24 Faulk Pharmaceuticals, Inc Methods and materials for targeting and affecting selected cells

Also Published As

Publication number Publication date
WO2004096254A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
EP2269656A3 (en) Selected antibodies binding to anionic phospholipids and aminophospholipids and their use in treatment
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
EP0954340A4 (en) Targeted combination immunotherapy of cancer
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
AU2002339865A8 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
DE602005018043D1 (en) LIPOSOMAL FORMULATIONS WITH DIHYDROSPHENOMYLININ AND METHOD FOR THEIR USE
WO2004110390A3 (en) Anti-cd74 immunoconjugates and methods
Summer et al. Cyclic versus noncyclic chelating scaffold for 89Zr-labeled ZEGFR: 2377 affibody bioconjugates targeting epidermal growth factor receptor overexpression
SG160425A1 (en) Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
AU2018224486A1 (en) Immunocytokine combination therapy
MX2008008185A (en) De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy.
AU2002365365A1 (en) Metal complex compounds
IL108322A0 (en) Metal complexes and metal complex conjugates of endotheline derivatives, methods for the preparation thereof and diagnostic compositions containing the same
MXPA03004499A (en) Repinotan kit.
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
WO2004096254A3 (en) Transferrin conjugates for tumor treatment
WO2001070255A3 (en) Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
DK1189627T3 (en) Compositions containing soluble forms of HLA-G for the treatment of inflammatory pathological conditions in the skin
AU2001233912A1 (en) Diagnosis of breast cancer using bcmp-81 as marker
EP1611151A4 (en) Stq-peptides
WO2003086041A3 (en) Binding agents and their use in targeting tumor cells
WO2004058803A3 (en) Peptides that bind of the vegfr-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase